Article citationsMore >>

Creon (pancrelipase) [package insert]. Abbott Laboratories, North Chicago, IL; 2012.

has been cited by the following article:

Article

Celiac Disease Pipeline: An Examination of New Treatment Options Currently Under Investigation

1University of Rhode Island College of Pharmacy, Kingston, Rhode Island


International Journal of Celiac Disease. 2018, Vol. 6 No. 2, 33-36
DOI: 10.12691/ijcd-6-2-8
Copyright © 2018 Science and Education Publishing

Cite this paper:
Eric P. Borrelli Pharm D. Celiac Disease Pipeline: An Examination of New Treatment Options Currently Under Investigation. International Journal of Celiac Disease. 2018; 6(2):33-36. doi: 10.12691/ijcd-6-2-8.

Correspondence to: Eric  P. Borrelli Pharm D, University of Rhode Island College of Pharmacy, Kingston, Rhode Island. Email: ericborrelli@my.uri.edu

Abstract

Celiac disease is a chronic gastrointestinal autoimmune disease that occurs in approximately 0.5-1% of the U.S. population. At this point in time there is no cure nor therapeutic option available for patients with CD. The only treatment option is a 100% strict adherence to a gluten free diet. However, even complete adherence may not be enough as some foods might contain cross contaminated gluten. The purpose of this study was to analyze and describe different therapy options currently being investigated for potential use in patients with CD. An analysis of ClinicalTrials.gov was performed with the search term “Celiac Disease”. The search returned 192 results, however only 8 were pharmacologic treatment options. The pharmacologic therapies located were TIMP-GLIA, ALV003, AMG714, pancrelipase, Nexvax2, RO5459072, Hu-Mik Beta-1, and Necator americanus (Na). With the nonexistent treatment options currently available, further research needs to be completed to create new therapeutic options for patients with CD with the goal of ultimately curing patients.

Keywords